Journal
CURRENT ONCOLOGY REPORTS
Volume 19, Issue 4, Pages -Publisher
SPRINGER
DOI: 10.1007/s11912-017-0587-4
Keywords
Non-small cell lung cancer (NSCLC).; Precision medicine; Targeted therapy; Molecular diagnostics; Next-generation sequencing (NGS); RNA sequencing; MET exon 14 skipping alteration; NTRK fusion
Categories
Funding
- [P30 CA008748]
- [T32 CA009207]
Ask authors/readers for more resources
Targeting genomic alterations has led to a paradigm shift in the treatment of patients with lung cancer. In an effort to better identify potentially actionable alterations that may predict response to FDA-approved and or investigational therapies, many centers have migrated towards performing targeted exome sequencing in patients with stage IV disease. The implementation of next-generation sequencing (NGS) in the evaluation of tumor tissue from patients with NSCLC has led to the discovery of targetable alterations in tumors that previously had no known actionable targets by less comprehensive profiling. An improved understanding of the molecular pathways that drive oncogenesis in NSCLC and a revolution in the technological advances in NGS have led to the development of new therapies through biomarker-driven clinical trials. This review will focus on the advances in molecular profiling that continue to fuel the revolution of precision medicine, identifying targets such as MET exon 14 skipping alterations and select recurrent gene alterations with increasing frequency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available